RECLAST

Manufacturer:

Novartis

Name:

RECLAST

HCPCS Code Descriptor:

Injection, zoledronic acid, 1 mg

Category:

J Code

HCPCS:

J3489

NDC(s):

70860-0802-82, 70860-0210-51, 00078-0435-61, 68001-0437-25, 67457-0920-05, 67457-0794-10, 67457-0619-10, 67457-0390-54, 63323-0966-00, 63323-0961-98, 55150-0266-05, 55111-0688-52, 55111-0685-07, 51991-0064-98, 51991-0065-98, 50742-0416-05, 47335-0962-41, 47335-0035-40, 43598-0330-11, 43598-0331-11, 25021-0830-82, 25021-0826-82, 25021-0826-67, 25021-0801-66, 23155-0170-31, 23155-0186-31, 16729-0242-31, 16714-0815-01, 00409-4215-01

Primary Type:

Osteoporosis

Generic Status:

Multi-Source

Route of Administration:

Intravenous

About:

RECLAST is an Osteoporosis drug manufactured by Novartis and administered via the Intravenous route of administration. The J Code: J3489 is aligned to the drug RECLAST.

Reclast is in the class of drugs called bisphosphonates. This medication is used to treat bone weakness disorders. It works by decreasing the rate at which the bones breakdown and helping bones keep their strength. Reclast is administered via intravenous infusion for a duration of approximately 15 minutes. This medication is a generic drug that is manufactured by many companies including Northstar RX, Accord Healthcare, Sagent pharmaceuticals, and others.